Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21 - PubMed (original) (raw)
. 1996 May 15;56(10):2411-6.
Affiliations
- PMID: 8625320
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21
C D Vocke et al. Cancer Res. 1996.
Abstract
To investigate the possible involvement of a tumor suppressor gene(s) on chromosome 8 in prostatic neoplasms, we performed a comprehensive loss of heterozygosity (LOH) study on 99 tumors from 97 prostate cancer patients. One of the carcinomas was a lymph node metastasis; the other 98 were primary carcinomas. Pure populations of carcinoma cells and normal epithelia were procured by tissue microdissection. Two separate tumor foci were obtained from each of two patients. Microsatellite markers from 25 loci on the short arm and one locus on the long arm of chromosome 8 were used for PCR-based LOH analysis on matched normal and tumor DNA samples. The overall LOH on 8p in this study was 85.9% (85 of 99) of carcinomas. The loss was highest at markers D8S133, D8S136, NEFL, and D8S137 (62,72, 64, and 75%, respectively), which are located at 8p12-21. Seventy-nine of 99 tumors exhibited loss in at least one of these four loci. In contrast, LOH at 8p22 was much lower: 17,18,18, and 19% at D8S549, D8S602, D8S254, and D8S261, respectively, with 25 of 99 tumors showing deletion in one or more of the four loci. All but 5 tumors with deletions in this more distal region had at least one retained locus between the 8p22 deletion and a more proximal region of loss at 8p12-21; 1 tumor had loss at 8p22 but not 8p12-21. This suggests there may be two distinct regions of loss and, therefore, two tumor suppressor genes on this chromosomal arm. The loss on 8p12-21 showed little or no correlation with grade or stage of disease.
Similar articles
- Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas.
Chuaqui RF, Sanz-Ortega J, Vocke C, Linehan WM, Sanz-Esponera J, Zhuang Z, Emmert-Buck MR, Merino MJ. Chuaqui RF, et al. Cancer Res. 1995 Nov 1;55(21):4995-8. Cancer Res. 1995. PMID: 7585541 - Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes.
Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P. Kagan J, et al. Oncogene. 1995 Nov 16;11(10):2121-6. Oncogene. 1995. PMID: 7478532 - Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer.
Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM, Westbrook CA. Yaremko ML, et al. Genes Chromosomes Cancer. 1996 Jul;16(3):189-95. doi: 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V. Genes Chromosomes Cancer. 1996. PMID: 8814452 - Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR, Kohn EC. Brown MR, et al. Gynecol Oncol. 1999 Jul;74(1):98-102. doi: 10.1006/gyno.1999.5439. Gynecol Oncol. 1999. PMID: 10385558 Review. - Tumour-suppressor genes in prostatic oncogenesis: a positional approach.
Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB. Bookstein R, et al. Br J Urol. 1997 Mar;79 Suppl 1:28-36. doi: 10.1111/j.1464-410x.1997.tb00798.x. Br J Urol. 1997. PMID: 9088270 Review.
Cited by
- Validation of potential RNA biomarkers for prostate cancer diagnosis and monitoring in plasma and urinary extracellular vesicles.
Brokāne A, Bajo-Santos C, Zayakin P, Belovs A, Jansons J, Lietuvietis V, Martens-Uzunova ES, Jenster GW, Linē A. Brokāne A, et al. Front Mol Biosci. 2023 Nov 30;10:1279854. doi: 10.3389/fmolb.2023.1279854. eCollection 2023. Front Mol Biosci. 2023. PMID: 38099195 Free PMC article. - NEFL is overexpressed and it modulates invasion and migration in neuroendocrine-like PC3-ML2 prostate cancer cells.
Burch TC, Mackay S, Hitefield NL, Roberts AB, Oduor IO, Nyalwidhe JO. Burch TC, et al. MicroPubl Biol. 2022 Oct 22;2022:10.17912/micropub.biology.000658. doi: 10.17912/micropub.biology.000658. eCollection 2022. MicroPubl Biol. 2022. PMID: 36345474 Free PMC article. - Deletion of NKX3.1 via CRISPR/Cas9 Induces Prostatic Intraepithelial Neoplasia in C57BL/6 Mice.
Park JJ, Kim JE, Jeon Y, Lee MR, Choi JY, Song BR, Park JW, Kang MJ, Choi HJ, Bae SJ, Lee H, Kang BC, Hwang DY. Park JJ, et al. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820964425. doi: 10.1177/1533033820964425. Technol Cancer Res Treat. 2020. PMID: 33094683 Free PMC article. - Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research.
Saranyutanon S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP. Saranyutanon S, et al. Cancers (Basel). 2020 Sep 17;12(9):2651. doi: 10.3390/cancers12092651. Cancers (Basel). 2020. PMID: 32957478 Free PMC article. Review. - CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.
Bowen C, Shibata M, Zhang H, Bergren SK, Shen MM, Gelmann EP. Bowen C, et al. Cancer Res. 2020 Nov 1;80(21):4805-4814. doi: 10.1158/0008-5472.CAN-20-1742. Epub 2020 Sep 17. Cancer Res. 2020. PMID: 32943441 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical